Immune-related adverse events in various organs caused by immune checkpoint inhibitors

Current cancer immunotherapies target immune checkpoint molecules such as the inhibitory receptor programmed cell death-1 (PD-1), one of its ligands, programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), a competitive ligand for CD28 binding to stimulatory receptors...

Full description

Bibliographic Details

Published in:	Allergology International
Main Authors:	Naoko Okiyama, Ryota Tanaka
Format:	Article
Language:	English
Published:	Elsevier 2022-04-01
Subjects:	Biologics Immune checkpoint inhibitor Immune-related adverse event Programmed cell death ligand T cell
Online Access:	http://www.sciencedirect.com/science/article/pii/S1323893022000028